A Study of Lemborexant in Chinese Participants With Insomnia Disorder

• Sponsor: Eisai Co., Ltd. (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT04549168
• Collaborator: (none)
• Enrollment: 700
• Locations: 23
• Arms: 2
• Anticipated Duration (Months): 24.1
• Patients Per Site: 30.4
• Patients Per Site Per Month: 1.3

Study Details

Study Description

Brief Summary

The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant 10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to persistent sleep (LPS) during the last 2 nights of 1 month of treatment in participants with insomnia disorder.

Condition or Disease	Intervention/Treatment	Phase
Sleep Initiation and Maintenance Disorders	Drug: Lemborexant; Drug: Placebo	Phase 3

Detailed Description

The study will have 2 phases: the Prerandomization Phase and the Randomization Phase. The Prerandomization Phase will comprise 3 periods that will last up to a maximum of 35 days: a Screening Period, a Run-in Period, and a Baseline Period. The Randomization Phase will comprise a Treatment Period during which participants will be treated for 30 nights (1 month) and a minimum 14-day Follow-up Period before an End of Study (EOS) Visit (up to 54 days). The total study duration for each participant on this study is 89 days.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 700 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects With Insomnia Disorder
• Actual Study Start Date: Nov 6, 2020
• Anticipated Primary Completion Date: Nov 11, 2022
• Anticipated Study Completion Date: Nov 11, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Lemborexant 10 mg Participants will receive one lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.	Drug: Lemborexant; Lemborexant 10 mg tablet.; Other Names: E2006
Placebo Comparator: Placebo Participants will receive one placebo matched to lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.	Drug: Placebo; Placebo tablet matched to lemborexant 10 mg tablet.

Outcome Measures

Primary Outcome Measures

1. Change from Baseline in Objective Latency to Persistent Sleep (LPS) During the Last 2 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to last 2 nights (Nights 29 and 30)]

   LPS is the duration of time measured from lights off to the first epoch of 20 consecutive epochs of non-wakefulness. Here, change from baseline value will be analyzed from the mean LPS of last two nights and baseline value.

Secondary Outcome Measures

1. Change from Baseline in Objective Sleep Efficiency (SE) During the Last 2 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to last 2 nights (Nights 29 and 30)]

   SE is the percentage of time spent asleep per time in bed (TIB), calculated as total sleep time (TST)/interval from lights off until lights on.

2. Change from Baseline in Objective Wake After Sleep Onset (WASO) During the Last 2 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to last 2 nights (Nights 29 and 30)]

   WASO is defined as minutes of wake from the onset of persistent sleep until lights on.

3. Change from Baseline in Subjective Sleep Onset Latency (sSOL) During the Last 7 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to last 7 nights (Nights 24 to 30)]

   sSOL is defined as estimated minutes from the time that the participant attempts to sleep until sleep onset. sSOL is defined as the time that the participant estimates it took him/her to fall asleep.

4. Change from Baseline in Subjective Sleep Efficiency (sSE) During the Last 7 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to last 7 nights (Nights 24 to 30)]

   sSE is defined as percentage of subjective total sleep time (sTST) divided by subjective time spent in bed, calculated as the interval from the time the participant reported attempting to sleep until the time participant stopped trying to sleep for the night.

5. Change from Baseline in Subjective Wake After Sleep Onset (sWASO) During the Last 7 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to last 7 nights (Nights 24 to 30)]

   sWASO is defined as sum of estimated minutes of wake during the night after initial sleep onset until the time the participant stopped trying to sleep for the night.

6. Change from Baseline in Polysomnography (PSG) Parameters (LPS, SE, WASO) During the First 2 Nights of 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo [Baseline to first 2 nights (Nights 1 and 2)]

   LPS is the duration of time measured from lights off to the first epoch of 20 consecutive epochs of non-wake. SE is the percentage of time spent asleep per TIB, calculated as TST/interval from lights off until lights on. WASO is defined as minutes of wake from the onset of persistent sleep until lights on.

7. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Up to Day 89]

8. Change from Baseline in Insomnia Severity After 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo as Assessed by Insomnia Severity Index (ISI) Total Score [Baseline to Day 31]

   The ISI is a 7-item self-report questionnaire assessing the nature, severity and impact of insomnia. The 7 dimensions evaluated are severity of: sleep onset; sleep maintenance; early-morning awakening problems; sleep dissatisfaction; interference of sleep difficulties with daytime functioning; noticeability of the sleep problems by others; and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item (from 0= no problem, 1= satisfied, 2= moderately satisfied, 3= dissatisfied and 4=very severe problem), yielding a total score from 0 to 28. A higher score indicates more severe illness.

9. Change from Baseline in Daytime Functioning After 1 Month of Treatment with Lemborexant 10 mg Compared to Placebo as Assessed by ISI Score Based on the 4 Items Related to Daily Function [Baseline to Day 31]

   The ISI is a 7-item self-report questionnaire assessing the nature, severity and impact of insomnia. The 4 dimensions out of 7 evaluated for daily functioning are severity of: sleep dissatisfaction; interference of sleep difficulties with daytime functioning; noticeability of the sleep problems by others; and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item (from 0= no problem, 1= satisfied, 2= moderately satisfied, 3= dissatisfied and 4=very severe problem), yielding a total score from 0 to 16. A higher score indicates more severe illness.

10. Number of Participants with Rebound Insomnia as Assessed by Sleep Diary [Up to Day 89]

    Rebound insomnia is defined as worsened sleep relative to screening after study drug treatment is completed. Sleep diary data from the follow-up period will be compared to sleep diary data from the screening period to assess whether participants experience rebound insomnia.

11. Change from Baseline in Mean Morning Residual Sleepiness Evaluated During Treatment and Following Completion of Treatment with Lemborexant [Baseline to Day 89]

    Change from baseline of the mean of morning sleepiness item on the sleep diary for the first 7 mornings of the Treatment Period, the last 7 mornings of the Treatment Period, as well as the means of the first 7 days and second 7 days of the Follow-up Period will be analyzed using mixed effect model repeated measurement (MMRM) assuming missing at random (MAR).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Participants must meet all of the following criteria to be included in this study:

1. Chinese male or female, age 18 years or older, at the time of informed consent (in Taiwan only participants with age 20 years or older are eligible)

2. Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Insomnia Disorder, as follows:

• Complains of dissatisfaction with night time sleep, in the form of difficulty staying asleep and/or awakening earlier in the morning than desired despite adequate opportunity for sleep

• Frequency of complaint greater than or equal to (>=) 3 times per week

• Duration of complaint >=3 months

• Associated with complaint of daytime impairment

1. At Screening: History of sSOL >=30 minutes on at least 3 nights per week in the previous 4 weeks and/or sWASO >=60 minutes on at least 3 nights per week in the previous 4 weeks

2. At Screening: Reports regular time spent in bed, either sleeping or trying to sleep, between 7 and 9 hours

3. At second Screening Visit (Visit 2a) and Run-in Visit (Visit 3a): Sleep diary confirms regular bedtime, defined as the time the participant attempts to sleep, between 21:00 and 01:00 on at least 5 of the final 7 nights and regular waketime, defined as the time the participant gets out of bed for the day, between 05:00 and 10:00 on at least 5 of the final 7 nights

4. At Screening and Baseline: ISI score >=15

5. Confirmation of current insomnia symptoms, as determined from responses on the sleep diary on the 7 most recent mornings before the first PSG during Screening Period (Visit 2a) and Run-in visit (Visit 3a), such that sSOL >=30 minutes on at least 3 of the 7 nights and/or sWASO >=60 minutes on at least 3 of the 7 nights

6. At the second Screening Visit (Visit 2a) and the Run-in visit (Visit 3a): Confirmation of sufficient duration of time spent in bed, as determined from responses on the sleep diary on the 7 most recent mornings before the Visit, such that there are no more than 2 nights with time spent in bed duration less than (<) 7 hours or greater than (>) 10 hours

7. During the Run-in Period, objective (PSG) evidence of insomnia as follows:

8. LPS average >=30 minutes on the 2 consecutive Baseline PSGs, with neither night <20 minutes and/or

9. WASO average >=60 minutes on the two consecutive Baseline PSGs, with neither night <45 minutes

10. Willing and able to comply with all aspects of the protocol, including staying in bed for at least 7 hours each night

11. Willing not to start a behavioral or other treatment program for the treatment of insomnia during the participant's participation in the study

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study:

1. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin test). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug

2. Females of childbearing potential who: Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

• total abstinence (if it is their preferred and usual lifestyle)

• an intrauterine device or intrauterine hormone-releasing system

• a contraceptive implant

• an oral contraceptive (participant must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation)

• have a vasectomized partner with confirmed azoospermia

• do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, that is, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)

1. Any history of a medical or psychiatric condition that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments

2. A prolonged corrected QT interval by Fredericia's formula (QTcF) interval (QTcF >450 millisecond [ms]) as demonstrated by a repeated electrocardiogram. A history of risk factors for torsade de pointes (for example, heart failure, hypokalemia, family history of long QT Syndrome) or the use of concomitant medications that prolonged the QTcF interval

3. Any suicidal ideation with intent with or without a plan at Screening or within 6 months of Screening

4. Any suicidal behavior in the past 10 years

5. Evidence of clinically significant disease (for example, cardiac; respiratory including chronic obstructive pulmonary disease, acute and/or severe respiratory depression; gastrointestinal; moderate and severe hepatic impairment; renal including severe renal impairment; neurological including myasthenia gravis; psychiatric disease; or malignancy within the past 5 years other than adequately treated basal cell carcinoma) or chronic pain that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments. Participants for whom a sedating drug would be contraindicated for safety reasons because of the participant's occupation or activities are also excluded

6. Hypersensitivity to lemborexant or to their excipients

7. Scheduled for surgery during the study

8. Known to be human immunodeficiency virus positive

9. Active viral hepatitis (B or C) as demonstrated by positive serology

10. History of drug or alcohol dependency or abuse within approximately the last 2 years

11. A current diagnosis of sleep-related breathing disorder including obstructive sleep apnea (with or without continuous positive airway pressure treatment), periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, or narcolepsy, or an exclusionary score on screening instruments to rule out individuals with symptoms of certain sleep disorders other than insomnia as follows:

• Snoring, Tiredness, Observed apnea, high blood Pressure (STOP)-Body mass index (BMI), Age, Neck circumference, and Gender (BANG) score >=5

• International Restless Legs Scale score >=16

1. Apnea-hypopnea Index >15 or Periodic Limb Movement with Arousal Index >15 as measured on the PSG at the second Screening Visit

2. Reports symptoms potentially related to narcolepsy, that in the clinical opinion of the investigator indicates the need for referral for a diagnostic evaluation for the presence of narcolepsy

3. Reports a history of sleep-related violent behavior, or sleep driving, or any other complex sleep-related behavior (for example, making phone calls or preparing and eating food while sleeping)

4. For participants who underwent diagnostic PSG within 1 year before informed consent:

• Age 18 to 64 years: Apnea Hypopnea Index >=10, or Periodic Limb Movements with Arousal Index >=10

• Age >=65 years: Apnea Hypopnea Index >15, or Periodic Limb Movements with Arousal Index >15

1. Beck Depression Inventory-II score >19 at Screening

2. Beck Anxiety Inventory score >15 at Screening

3. Habitually naps during the day more than 3 times per week

4. Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine containing beverages after 18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her participation in the study. Participants are excluded if, in the previous 3 months, they had symptoms that would meet DSM-5 criteria for caffeine intoxication, which includes consumption of a high dose of caffeine (significantly in excess of 250 mg) and >=5 of the following symptoms: restlessness, nervousness, excitement, insomnia, flushed face, diuresis, gastrointestinal disturbance, muscle twitching, rambling flow of thought and speech, tachycardia or cardiac arrhythmia, periods of high energy, or psychomotor agitation. To be exclusionary, those symptoms must cause distress or impairment in social, occupational and other forms of functioning, and not be associated with other substance, mental disorder or medical condition

5. Reports habitually consuming more than 14 drinks containing alcohol per week (females) or more than 21 drinks containing alcohol per week (males), or unwilling to limit alcohol intake to no more than 2 drinks per day or forego having alcohol within the 3 hours before bedtime for the duration of his/her participation in the study

6. Excluding comorbid nocturia that is causing or exacerbating the insomnia

7. Used any prohibited prescription or over-the-counter concomitant medications within 1 week or 5 half-lives, whichever is longer, before the first dose of study medication (Run-in Period)

8. Used any modality of treatment for insomnia, including cognitive behavioral therapy or marijuana within 1 week or 5 half-lives, whichever is longer, before the first dose of study medication (Run-in Period)

9. Failed treatment with dual orexin receptor antagonist drugs (efficacy and/or safety) following treatment with an appropriate dose and of adequate duration in the opinion of the investigator

10. Transmeridian travel across more than 3 time zones in the 2 weeks before Screening, or between Screening and Baseline, or plans to travel across more than 3 time zones during the study (China mainland will be considered as 1 time zone)

11. A positive drug test at Screening, Run-in, or Baseline, or unwilling to refrain from use of recreational drugs during the study

12. Currently enrolled in another clinical trial or used any investigational drug or device within 30 days or 5 half-lives, whichever is longer preceding informed consent

13. Previously participated in any clinical trial of lemborexant

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Beijing Tiantan Hosptial, Capital Medical University	Beijing	Beijing	China
2	Peking University Sixth Hospital	Beijing	Beijing	China
3	Xuanwu Hospital Capital Medical University	Beijing	Beijing	China
4	Daping Hospital	Chongqing	Chongqing	China
5	The First Affiliated Hospital of Jinan University	Guangzhou	Guangdong	China
6	The First Hospital of Hebei Medical University	Shijiazhuang	Hebei	China
7	The Third Hospital of Hebei Medical University	Shijiazhuang	Hebei	China
8	Henan Mental Health Center	Xinxiang	Henan	China
9	Wuhan Mental Health Center	Wuhan	Hubei	China
10	Nanjing Brain Hosptial	Nanjing	Jiangsu	China
11	The Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu	China
12	The Second Affiliated Hospital of Nanchang University	Nanchang	Jiangxi	China
13	Jilin First University Affiliated Hospital	Changchun	Jilin	China
14	Inner Mongolia Autonomous Region Peoples Hospital	Hohhot	Mongolia	China
15	Tangdu Hospital	Xian	Shaanxi	China
16	Shandong Provincial Qianfushan Hospital	Jinan	Shandong	China
17	Huashan Hospital Fudan University	Shanghai	Shanghai	China
18	Shanghai Mental Health Center	Shanghai	Shanghai	China
19	First Hospital of Shanxi Medical University	Taiyuan	Shannxi	China
20	West China Hospital	Chengdu	Sichuan	China
21	Tianjin Anding Hospital	Tianjin	Tianjin	China
22	Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital	Taoyuan	Taipei	Taiwan
23	Taipei Veterans General Hospital	Taipei		Taiwan

Sponsors and Collaborators

• Eisai Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Eisai Co., Ltd.
• ClinicalTrials.gov Identifier: NCT04549168
• Other Study ID Numbers: E2006-J086-311
• First Posted: Sep 16, 2020
• Last Update Posted: Apr 8, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Eisai Co., Ltd.: Insomnia disorder; Lemborexant; Chinese Participants; E2006
• Additional relevant MeSH terms: Sleep Initiation and Maintenance Disorders; Disease; Lemborexant

Study Results

No Results Posted as of Apr 8, 2022